XOMA Royalty Corporation (XOMA)
NASDAQ: XOMA · Real-Time Price · USD
31.73
-0.02 (-0.06%)
Nov 24, 2025, 4:00 PM EST - Market closed
XOMA Royalty Employees
XOMA Royalty had 13 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
13
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$3,623,538
Profits / Employee
$758,154
Market Cap
393.78M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 13 | 0 | - |
| Dec 31, 2023 | 13 | 0 | - |
| Dec 31, 2022 | 13 | 1 | 8.33% |
| Dec 31, 2021 | 12 | 2 | 20.00% |
| Dec 31, 2020 | 10 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
XOMA News
- 3 days ago - XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V. - GlobeNewsWire
- 12 days ago - XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements - GlobeNewsWire
- 5 weeks ago - XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement - GlobeNewsWire
- 7 weeks ago - XOMA Royalty PFD Update: Going Back To My Original Sell Ratings - Seeking Alpha
- 7 weeks ago - XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V. - GlobeNewsWire
- 2 months ago - ESSA Pharma Inc. Amends Agreement with XenoTherapeutics - PRNewsWire
- 2 months ago - XOMA Royalty Declares Quarterly Preferred Stock Dividends - GlobeNewsWire
- 2 months ago - XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc. - GlobeNewsWire